PEPTETF

REX Shares launched the REX Peptide ETF (PEPT), offering global exposure to peptide drug developers, manufacturers, and delivery platforms. The fund tracks the VettaFi Peptide Index and charges 65 bps in fees.

With GLP-1 adoption expanding and the global incretin market projected to reach $200 billion by 2030, the peptide market is positioned for significant growth. PEPT competes with similar ETFs THNR and OZEM, which charge 59 bps each.